Laval, Quebec
Today, the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, and the Honourable Marjorie Michel, Minister of Health, along with Stéphane Bancel, Chief Executive Officer of Moderna, announced that Moderna has achieved a major milestone, producing the first made-in-Canada doses of its COVID-19 vaccine at its new state-of-the-art mRNA vaccine biomanufacturing facility in Laval, Quebec.
This milestone represents a concrete step forward in the government's efforts to build a domestic vaccine supply chain. The new Laval facility will strengthen Canada's ability to respond swiftly to public health emergencies. Moderna's operations in Canada, which also involve the establishment of domestic research and development partnerships and a partnership with Novocol Pharma's fill-finish facility in Cambridge, Ontario, all underscore the company's commitment to Canada's life sciences industry, economic growth and scientific innovation. The opening of Moderna's facility and its production of domestically manufactured vaccines mark a new era of made-in-Canada innovation and biomanufacturing.
